The investor rights law firm said it is preparing a potential securities class action after Disc Medicine shares fell when the FDA issued a Complete Response Letter on the company’s bitopertin program.
Rosen Law Firm said it is continuing to investigate potential securities claims on behalf of Disc Medicine, Inc. shareholders over allegations that the company may have issued materially misleading business information. The firm said it is preparing a class action and that investors who purchased Disc Medicine securities may be able to seek compensation through a contingency fee arrangement. The matter centers on February 13, 2026, when the U.S. Food and Drug Administration issued a Complete Response Letter to Disc Medicine regarding its bitopertin program. The FDA said it could not approve Disc Medicine’s new drug application because there were uncertainties in the application that would require additional evidence. Disc Medicine shares fell 22% on February 13, 2026, following the notice. Rosen Law Firm directed investors seeking to join the prospective class action to submit information through its case page, call Phillip Kim, Esq. at 866-767-3653, or email the firm for details. Securities class actions are lawsuits brought by investors who claim they were harmed by allegedly misleading disclosures.